Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

838.78 +16.82 (+2.05%)
Streaming Delayed Price Updated: 12:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today? ↗
Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. 
Via InvestorPlace
News headline image
Why Is Argenx (ARGX) Stock Up 27% Today? ↗
Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
News headline image
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
The Latest Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
Analyst Expectations for argenx's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for argenx ↗
 
Via Benzinga
News headline image
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
News headline image
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
This Emerging Market Could Be the Next Big Thing in Biotech ↗
Medicines to treat the many symptoms of long COVID are in high demand already. 
Via The Motley Fool
News headline image
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
News headline image
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
News headline image
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
News headline image
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults ↗
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or... 
Via Benzinga
News headline image
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease ↗
The European Union has reco 
Via Benzinga
News headline image
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
News headline image
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
From argenx SE
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023 ↗
 
Via Benzinga
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday ↗
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares... 
Via Benzinga
News headline image
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2023 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
From argenx SE
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗
 
Via Benzinga
News headline image
7 Biotech Stocks That Could Cure Your Portfolio Woes ↗
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
News headline image
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
From argenx SE
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.